Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 331

Sort by

Sort Order Select

Journal Articles

Don’t let the genie out of the bottle!

Shaji Kumar

Blood (2024) 143 (7): 564–566.

https://doi.org/10.1182/blood.2023023293

Published: 2024

Journal Articles

Monoclonal gammopathy of thrombotic/thrombocytopenic significance

Adam J. Kanack, Jordan K. Schaefer, Meera Sridharan, Noah P. Splinter, Mindy C. Kohlhagen, Bandana Singh, Silvana B. De Lorenzo, Emily E. Mauch, Maen A. Hussein, Marwan Shaikh, Shaji Kumar, Renren Wen, Demin Wang, David Murray, Anand Padmanabhan

Blood (2023) 141 (14): 1772–1776.

https://doi.org/10.1182/blood.2022018797

Published: 2023

Includes: Supplemental data

Journal Articles

Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance

Blood (2022) 140 (18): 1997–2000.

https://doi.org/10.1182/blood.2022017616

Published: 2022

Includes: Supplemental data

Journal Articles

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla-Martinez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Dogan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesus San-Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana Advani, Stephen Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando Lopez-Guillermo, Maria Victoria Mateos, Elizabeth Macintyre, Ari M. Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano A. Pileri, Miguel Piris, Barbara Pro, Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier-Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz

Blood (2022) 140 (11): 1229–1253.

https://doi.org/10.1182/blood.2022015851

Published: 2022

Includes: Supplemental data

Journal Articles

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Blood (2022) 139 (6): 835–844.

https://doi.org/10.1182/blood.2021011101

Published: 2022

Includes: Supplemental data

Journal Articles

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Blood (2022) 139 (4): 492–501.

https://doi.org/10.1182/blood.2020010439

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Shaji Kumar, Anita D'Souza, Nina Shah, Cesar Rodriguez, Peter M. Voorhees, Orlando F. Bueno, Ben Buelow, Kevin J. Freise, Susan Yue, Rajvineeth Kumar Pothacamury, Akshanth R. Polepally, Ravi Vij

Blood (2021) 138 (Supplement 1): 900.

https://doi.org/10.1182/blood-2021-150757

Published: 2021

Journal Articles

Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Wilson I Gonsalves, Shaji Kumar, Gabriela Perez, Stephanie Saathoff, Diana M Wilson, Anna Young, Sikander Ailawadhi

Blood (2021) 138 (Supplement 1): 2735.

https://doi.org/10.1182/blood-2021-149437

Published: 2021

Journal Articles

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Blood (2021) 138 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2021-149594

Published: 2021

Journal Articles

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Blood (2021) 138 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2021-149222

Published: 2021

Journal Articles

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2742.

https://doi.org/10.1182/blood-2021-148385

Published: 2021

Journal Articles

Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Multiple Myeloma Patients at Mayo Clinic

Scott Soefje, Corinne Carpenter, Katherine Carlson, Samir Awasthi, Thomas S. Lin, Shuchita Kaila, Daniel Tarjan, Nikhil Kayal, Christian Kirkup, Tyler Wagner, Kathleen Gray, Shaji Kumar

Blood (2021) 138 (Supplement 1): 2717.

https://doi.org/10.1182/blood-2021-149012

Published: 2021

Journal Articles

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Blood (2021) 138 (Supplement 1): 2733.

https://doi.org/10.1182/blood-2021-148481

Published: 2021

Journal Articles

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Blood (2021) 138 (Supplement 1): 2746.

https://doi.org/10.1182/blood-2021-152681

Published: 2021

Journal Articles

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2021-151859

Published: 2021

Journal Articles

Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART

Yan Asmann, Ying Li, Taxiarchis Kourelis, Moritz Binder, Wilson I Gonsalves, Henan Zhang, Anatilde Gonzalez Guerrico, Zuoyi Shao, Prashant Kapoor, David Dingli, Rahma M Warsame, Haidong Dong, Shaji Kumar, Yi Lin

Blood (2021) 138 (Supplement 1): 3838.

https://doi.org/10.1182/blood-2021-153254

Published: 2021

Journal Articles

Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study

Blood (2021) 138 (Supplement 1): 3885.

https://doi.org/10.1182/blood-2021-149306

Published: 2021

Journal Articles

False-Negative Centromere 15 Probe Results in Association with African Ancestry in Plasma Cell Dyscrasias

Alaa Koleilat, Hongwei Tang, James B Smadbeck, Neeraj Sharma, Kathryn E. Pearce, Eran Elhaik, Michael L. Baird, Yan Asmann, Patricia Greipp, Jess F Peterson, Rhett P. Ketterling, S. Vincent Rajkumar, Shaji Kumar, Linda B Baughn

Blood (2021) 138 (Supplement 1): 4101.

https://doi.org/10.1182/blood-2021-152654

Published: 2021

Journal Articles

Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

Blood (2021) 138 (Supplement 1): 4095.

https://doi.org/10.1182/blood-2021-150369

Published: 2021

Journal Articles

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Nnadozie Emechebe, Shaji Kumar, Hartmut Goldschmidt, Maria-Victoria Mateos, Juan Du, Kihyun Kim, Giampaolo Merlini, Meletios A. Dimopoulos, Heinz Ludwig, Hiroshi Handa, Carlos Fernandez de Larrea, Donna E. Reece, Wenming Chen, Noopur S. Raje, Sudeep Karve, Emma Arriola, Jeremy A. Ross, Brian G.M. Durie

Blood (2021) 138 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2021-149270

Published: 2021

NARROW

Don’t let the genie out of the bottle!

Monoclonal gammopathy of thrombotic/thrombocytopenic significance

Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Multiple Myeloma Patients at Mayo Clinic

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART

Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study

False-Negative Centromere 15 Probe Results in Association with African Ancestry in Plasma Cell Dyscrasias

Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only